A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson's disease

Reviews in the Neurosciences

Volumn 23, Issue 2, 2012, Pages 199-226

  Willis, Gregory L ^a   Moore, Cleo ^a   Armstrong, Stuart M ^a  

^a Bronowski Clinic   (Australia)

Author keywords

circadian; dopamine overdosing; dopamine replacement; light therapy; melatonin; Parkinson's disease; total drug burden

Indexed keywords

AMANTADINE; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; DOPAMINE; ENTACAPONE; LEVODOPA; MELATONIN; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TRIHEXYPHENIDYL;

ADULT; AGED; ANXIETY; BALANCE DISORDER; BRADYKINESIA; CIRCADIAN RHYTHM; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DYSKINESIA; HUMAN; INSOMNIA; LATENT PERIOD; MAJOR CLINICAL STUDY; MORBIDITY; MOTOR PERFORMANCE; NEOPLASM; NEUROLOGIC DISEASE; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PHOTOTHERAPY; PRIORITY JOURNAL; RETINA; RETROSPECTIVE STUDY; REVIEW; SUBSTITUTION THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; WALKING;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CIRCADIAN CLOCKS; COMBINED MODALITY THERAPY; DEPRESSION; DOPAMINE; DOPAMINE AGONISTS; HISTORY, 21ST CENTURY; HUMANS; MALE; MELATONIN; MIDDLE AGED; OVERDOSE; PARKINSON DISEASE; PHOTOTHERAPY; PSYCHOMOTOR PERFORMANCE; RETINA; RETROSPECTIVE STUDIES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 84861069782     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/revneuro-2011-0072     Document Type: Review

References (145)

1. Abbott, A., (2006). While you were sleeping. Nature. 437 , 1220-1222.
2. Abilio, V.C., Silva, R.H., Carvalho, R.C., Grassl, C., Calzavara, M.B., Registro, S., D'Almeida, V. Ribeiro Rde, A. and Frussa-Filho, R. (2004). Important role of striatal catalase in aging and reserpineinduced oral dyskinaesia. Neuropharmocology 47 , 263-272.
3. Abilio, V.C., Vera, J.A. Jr., Ferreira, L.S., Duarte, C.R., Carvalho, R.C., Grassl, C., Martins, C.R., Torres-Leite, D., Bignotto, M., Tufik, S., et al. (2002). Effect of melatonin on orofacial movements in rats. Psychopharmacology 161 , 240-347.
4. Andrade, L.A., Lima, J.G., Tufik, S., Bertolucci, P.H., and Carlini, E.A. (1987). REM sleep deprivation in an experimental model of PD. Arquivos de Neuro-Psiquiatria 45 , 217-223.
5. Anisimov, V.N., Zavarzina, N.Y., Zabezhinski, M.A., Popovich, I.G., Zimina, O.A., Shtylik, A.V., Arutjunyan, A.V., Oparina, T.I., Prokopenko, V.M., Mikhalski, A.I., et al. (2001). Melatonin increases both life span and tumour incidence in female CBA mice. J. Gerontol. A. Biol. Sci. Med. Sci. 56 , B311-B323.
6. Artemenko, A.R. and Levin, Y.I. (1996). Light therapy of patients with Parkinsonism. Zh Neuropatol. Psikhiatr. Im. S.S. Korsakova 96 , 63-66.
7. Arunasmitha, S., Andrade, C., and Pradham, N. (1989). Biphasic effect of apomorphine on rodent motility. Ind. J. Physiol. Pharmacol. 33 , 132-133.
8. Asami, T., Kuribana, S., and Tadokoro, S. (1986). Effects of repeated administration of bromocryptine on ambulatory activity in mice, and changes in methamphetamine sensitivity in bromocryptineexperienced mice. Yakubutsu Seishin Kodo 6 , 309-317.
9. Backström, M. and Wetterberg, L. (1977). Influence of psoralen on melatonin formation in rat pineal gland in organ culture. Acta. Endocrinol. (Copenh.) 86 , 659-666.
10. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., and Seitelberger, F. (1973). Brain DA and the syndromes of Parkinson and Huntington. J. Neurol. Sci. 20 , 415-445.
11. Bertolucci, P.H., Andrade, L.A., Lima, J.G., and Carlini, E.A. (1987). Total sleep deprivation and PD. Arg. Neuropsiquiatr. 45 , 224-230.
12. Birkmayer, W. and Hornykiewicz, O. (1962) The L-dihydro xyphenylalanine (L-dopa) effect in Parkinson's syndrome in man: on the pathogenesis and treatment of Parkinson's akinesis. Arch. Psychiatr. Nervenkr. Z Gesamte Neurol. Psychiatr. 203 , 560-574.
13. Bodis-Wollner, I. (1990). Visual deficits related to DA deficiency in experimental animals and PD patients. Trends Neurosci. 13 , 296-302.
14. Bodis-Wollner, I. (1990). The visual system in PD. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 67 , 297-316.
15. Boeve, B.F., Silber, M.H., and Ferman, T.J. (2004). REM sleep behaviour disorders in PD and dementia with Lewy bodies. J. Geriatr. Psychiatr. Neurol. 17 , 146-157.
16. Bordet, R., Devos, D., Brigue, S., Touitou, Y., Guieu, J.D., Libersa, C., and Destee, A. (2003). Study of circadian melatonin secretion pattern at different stages of PD. Clin. Neuropharmacol. 26 , 65-72.
17. Borg, D.C. (1974). Free radicals in the human nervous system. Adv. Neurol. 5 , 277-286.
18. Boulamery, A., Simon, N., Vidal, J., and Bruguerolle, B. (2010). Effects of L-dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study. Chronobiol. Int. 27 , 251-264.
19. Brainard, G.C., Lewy, A.J., Menaker, M., Frederickson, R.H., Miller, L.S., Weleber, R.G., Cassone, V., and Hudson, D. (1988). Doseresponse relationship between light iridescence and the suppression of plasma melatonin in human volunteers. Brain Res. 457 , 212-218.
20. Bucci, L. (1974). The biphasic effect of small doses of tranylcypromine on the spontaneous motor activity and learning conditioned behavior in rats. J. Med. Chem. 18 , 437-438.
21. Burton, S., Daya, S., and Potgeiter, B. (1991). Melatonin modulates apomorphine-induced rotational behaviour. Experientia 47 , 466-469.
22. Burunate, E., Castro, R., Diaz-Palarea, M.D., and Rodriguez, M. (1988). Conditioning of the early behavioral response to apomorphine in the rotational model of PD. Eur. J. Pharmacol. 145 , 323-327.
23. Castro, R., Abrev, P., Calzadilla, C.H., and Rodriguez, M. (1985). Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on close interval. Psychopharmocologia (Berl.) 85 , 333-339.
24. Catala, M.D., Canete-Nicolas, C., Fradi, A., Tara Zona, P.J., Tormos, J.M., and Pascual-Leone, A. (1997). Melatonin levels in PD: drug therapy versus electrical stimulation of the internal globus pallidus. Exp. Gerontol. 32 , 553-558.
25. Ceravolo, R., Frosini, D., Rossi, C., and Bonuccelli, U. (2010). Spectrum of addictions in PD: from DA dysregulation syndrome to impulse control disorders. J. Neurol. 257 , S276-S286.
26. Cheng, H.C., Ulane, C.M., and Burke, R.E. (2010). Clinical progression in PD and the neurobiology of axons. Ann. Neurol. 67 , 715-725.
27. Christodoulou, G.N., Malliaras, D.E., Lykouras, E.P., Papadimitriou, G.N., and Stephanis, C.N. (1978). Possible prophylactic effect of sleep deprivation. Am. J. Psychiatry. 135 , 325-376.
28. Claveria, L.E., Calne, D.B., and Allen, J.G. (1973). 'On-off'phenomena related to high plasma levodopa. Br. Med. J. 2 , 641-643.
29. Cornelissen, G., Halberg, F., Tarquini, R., Perfetto, F., Salti, R., Laffi, G., and Otsuka, K. (2003). Point and interval estimations of melatonin ecphasia in Smith-Magenis Syndrome. Biomed. Pharmacother. 57 (Suppl. 1), 315-345.
30. Cotzias, G.C., Papavasiliou, P.S., Ginos, J., Steck, A., and Duby, S. (1971). Metabolic modifications of PD and of chronic manganese poisoning. Ann. Rev. Med. 22 , 305-326.
31. Critchley, E.M (1976). Letter: peak-dose dysphonia in parkinsonism. Lancet 1 , 544.
32. Dahlström, A. and Fuxe, K. (1964a) Evidence for the existence of monoamine-containing neurones in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurones. Acta Physiol. Scand. Suppl. 232 , 1-55.
33. Dahlström, A. and Fuxe, K. (1964b) Evidence for the existence of monoamine-containing neurones in the central nervous system. II. Experimentally induced changes in the intraneuronal amine levels of bulbospinal nerve systems. Acta Physiol. Scand. Suppl. 247 , 1-36.
34. Danguir, J. and Nicolaidis, S. (1980). Cortical activity and sleep in the rat lateral hypothalamic syndrome. Brain Res. 185 , 305-321.
35. Demet, E.M., Chicz-Demet, A., Fallon, J.H., and Sokolski, K.N., (1999). Sleep deprivation therapy in depressive illness and PD. Prog. Neuropsychopharmacol. Biol. Psych. 23 , 753-784.
36. Deniker, P., Ginestet, D., and Loo, H. (1975). Psychotropic drugs and mechanisms of mood regulators. Encephale 1 , 359-362.
37. De Pedro Cuestra, J. (1987). Studies of the prevalence of paralysis agitans by traces methodology. Acta. Neurol. Scand. (Suppl.) 112 , 1-106.
38. De Pedro Cuestra, J. and Stawiarz, L. (1991). PD incidences: magnitude, comparability, time trends. Acta. Neurol. Scand. 84 , 382-388.
39. Djamgoz, M.B., Hankins, M.W., Hirano, S.N., and Archer, S.N. (1997). Neurobiology of retinal DA in relation to degenerative states of the tissue. Vision Res. 37 , 3509-3529.
40. Dubocovich, M.L. (1983). Melatonin is a potent modulator of DA release in the retina. Nature (London) 306 , 782.
41. Duvoisin, R.C., Golbe, L.I., and Lepore, F.E. (1987). Progressive subnuclear palsy. Can. J. Neurol. Sci. 14 , 547-554.
42. Eastman, C. (1990). What the placebo literature can tell us about light therapy for SAD. Psychopharm. Bull. 26 , 495-504.
43. Fehling, C. (1966). Treatment of Parkinson's syndrome with L-dopa a double blind study. Acta Neurol. Scandiv. 42 , 367-372.
44. Feldmand, R.G. (1985). PD: Individualizing therapy. Hospital Practice 20: 185, 80 a-e,i,m,p,u.
45. Fertl, E., Auff, E., Dopplebauer, A., and Waldhauser, F. (1991). Circadian secretion pattern of melatonin in PD. J. Neural. Transm. 3 , 41-47.
46. Fink, J.S. and Smith, G.P. (1979) L-dopa repairs deficits in locomotor investigatory exploration produced by denervation of catecholamine terminal fields in the forebrain of rats. J. Comp. Phys. Psych. 93 , 66-73.
47. Fonda, D. (1985). PD in the elderly: psychiatric manifestations. Geriatrics 40 , 109-112.
48. Fraschini, F., Cesarani, A., Alpini, D., Esposti, D., and Stankov, B.M. (1999). Melatonin influences human balance. Biol. Sig. Recept. 8 , 111-119.
49. Fredriksson, A., Plaznik, A., Sandström, E., Jonsson, G., and Archer, T. (1990). MPTP Induced hypoactivity in mice; Reversal by L-Dopa. Pharmacol. Toxicol. 67 , 295-301.
50. Friedhoff, A.J., Hekimian, L., Alpert, M., and Tobach, E. (1963). Dihydroxyphenylalanine in extrapyramidal disease. J. Am. Med. Assoc. 184 , 285-286.
51. Fuxe, K. (1965). Evidence for the existence of monoamine neurones in the central nervous system: the monoamine nerve terminals. Z. Zellforsch. Mikrosk. Anat. 573-596.
52. Gerbaldo, H., Cassady, S., Maurer, K., and Pieschl, D. (1997). The assessment of light intensity preference in psychiatric patients: a questionnaire. Acta Psych. Scand. 95 , 236-241.
53. Girotti, F., Carella, F., Grassi, M.P., Soliveri, P., Marano, R., and Caraceni, T. (1986). Motor and cognitive performances of Parkinsonian patients in the on and off phase of the disease. J. Neurol. Neurosurg. Psychiatr. 49 , 657-660.
54. Goetz, C.G., Li, J.M., Wuu, J., and Leurgans, S. (2006). Does seasonal variation affect hallucinations in PD ? A longitudinal study. Mov. Disord. 21 , 863-865.
55. Govitrapong, P., Hama, Y., Pfeiffer, R., and Ebadi, M. (1989). Status of DA in bovine pineal glands and the stimulation of N-acetyltransferase activity by D2-DArgic receptor agonists in the rat pineal gland in culture. J. Pineal. Res. 6 , 17-31.
56. Gradinaru, V., Mogri, M., Thompson, K.R., Henderson, J.M., and Deisseroth, K. (2009). Optical deconstruction of Parkinsonian neural circuitry. Science 324 , 354-359.
57. Gravotta, L., Gavrila, A.M., Hood, S., and Air, S. (2011). Global depletion of dopamine using intracerebroventricular 6-hydroxydopamine injection disrupts normal circadian wheelrunning patterns and PERIOD2 expression in the rat forebrain. J. Mol. Neurosci. 45 , 162-171.
58. Guardiola-Le Maitre, B. (1997). Toxicology of melatonin. J. Biol. Rhythms 12 , 697-706.
59. Hadjiconstantinou, M. and Neff, N.H. (1984). Catecholamine systems of retina: a model for studying synaptic mechanisms. Life Sci. 35 , 1135-1147.
60. Hensman, D.J. and Bain, P.G. (2006). Levodopa can worsen tremor associated with dystonia. Mov. Disord. 21 , 1778-1780.
61. Hinson, V.K. (2010). PD and motor fluctuations. Curr. Treat Options. Neurol. 12 , 186-199.
62. Isaac, W. (1971). A study of the relationship between the visual system and the effects of d-amphetamine. Physiol. Behav. 6 , 157-159.
63. Iversen, S.D. (1971). The effect of surgical lesions to frontal cortex and substantia nigra in amphetamine responses in rats. Brain Res. 31 , 295-311.
64. Iversen, L.L. and Creese, I. (1978). Behavioral correlates of DArgic supersensitivity. Adv. Neurology 9 , 81-92.
65. Jackson, G.R. and Owsley, C. (2003). Visual dysfunction, neurodegenerative diseases and aging. Neurol. Clin. 21 , 709-728.
66. Kallman, W.M. and Isaac, W. (1975). The effects of age and illumination on the dose-response curves for three stimulants. Psychopharmacologia 40 , 313-318.
67. Kirsch, I. The emperor's new drugs (2010) (New York: Basic Books).
68. Larsen, J.K., Lindberg, M.L., and Skovgaard, B. (1976). Sleep deprivation as treatment for endogenous depression. Acta Psychiatr. Scand. 54 , 167-173.
69. Larsen, T.A., Calne, S., and Calne, D.B. (1984). Assessment of PD. Clin. Neuropharmacol. 7 , 165-169.
70. Leonard, K. (1931). Eigenartige tagesschwankingen des zustandbildes bei Parkinsonismus zuit. Fur dieges. Neurol. Psych. 134 , 76.
71. Likert, R.A. (1932). A technique for the measurements of attitudes. Arch. Psych. No. 140.
72. Louis, E.D., Winfield, L., Fahn, S., and Ford, B. (2001). Speech dysfluency exacerbated by levodopa in PD. Mov. Disord. 16 , 562-565.
73. McGeer, P.L., Boulding, J.E., Gibson, W.C., and Foulkes, R.G. (1961). Drug-induced extrapyramidal reactions. J. Am. Med. Assoc. 177 , 101-106.
74. Makman, M.H., Brown, J.H., and Mishra, R.K. (1975). Cyclic AMP in retina and caudate nucleus: influence of DA and other agents. Adv. Cyclic Nuclear Res. 5 , 661-679.
75. Marshall, J.F., Levitan, D., and Stricker, E.M. (1976). Activationinduced restoration of sensory-motor functions in rats with DA-depleting brain lesions. J. Comp. Physiol. Psych. 90 , 536-546.
76. Medeiros, C.A., Cavelhedo de Bruin, P.F., Lopes, L.A., Magalhaes, M.C., de Lourdes Seabra, M., and Sales de Bruin, V.M. (2007). Effects of exogenous melatonin on sleep and motor dysfunction in PD: a randomized, double-blind, placebo controlled study. J. Neurol. 254 , 459-464.
77. Mercuri, N.B., Calabresi, P., and Bernardi, G. (1992). The electrophysiological actions of DA and DArgic drugs on neurons of the substantia nigra pars compacta and ventral tegmental area. Life Sci. 51 , 711-718.
78. Messiha, F.S. (1989). Mouse strain-dependent effect of amantadine on motility and brain biogenic amines. Arch. Int. Pharmocodyn. Ther. 302 , 74-85.
79. Mindham, R.H., Marsden, C.D., and Parkes, J.D. (1976). Psychiatric symptoms during L-dopa therapy for PD and the relationship to physical disability. Psychol. Med. 6 , 23-33.
80. Morella, M., Carboni, E., Devoto, S., and Di Chiara, G. (1987). 6-Hydroxydopamine lesions reduce specific (3H) sulpiride binding in the rat substantia nigra: direct evidence for the existence of nigral D-2 autoreceptors. Eur. J. Pharmacol. 140 , 99-104.
81. Müller, C.P. and Huston, J.P. (2007). Dopamine activity in the occipital and temporal cortex of rats: dissociating effects of sensory but not pharmacological stimulation. Synapse 61 , 254-258.
82. Müller, C.P., de Souza Silva, M.A., and Huston, J.P. ( 2007). Double dissociating effects of sensory stimulation and cocaine on serotonin activity in the occipital and temporal cortices. Neuropharmacology 52 , 854-862.
83. National Institute for Health and Clinical Excellence (NICE) Clinical Guideline 35. The National Collaborative Centre for Chronic Conditions, London, 2006.
84. Navarro, A., Tolivia, J., and Alvarez-Uria, M. (1999). Size of degeneration increases in herring bodies during aging in hamsters. Histol. Histopathol. 14 , 1093-1099.
85. Naylor, R.J. and Olley, J.E. (1972). Modification of the behavioral changes induced by amphetamine in the rat by lesions in the caudate nucleus, the caudate putamen and globus pallidus. Neuropharmacology 11 , 91-99.
86. Noble, C.S. (1973). Effect of lesions in the ventromedial and ventrolateral midbrain of rats on several behaviours. Ph.D. Dissertation, University of Georgia, Athens, Georgia, USA.
87. Nutt, J.G., Gancher, S.T., and Woodward, W.R. (1988). Does an inhibitory action of levodopa contribute to motor fluctuations ? Neurology 38 , 1553-1557.
88. Oakin-Bendahan, S., Anis, Y., Nir, I., and Zisapel, N. (1995). Effects of long term administration of melatonin and a putative antagonist on the aging rat. Neuroreport 6 , 785-788.
89. O'Brien, I.A., Lewin, I.G., O'Hare, J.P., Arendt, J., and Corrall, R.J. (1986). Abnormal circadian rhythm of melatonin in diabetic autonomic neuropathy. Clin. Endocrinol. (Oxf) 24 , 359-364.
90. Okun, M.S. and Watts, R. (2002). Depression associated with PD. Clinical factors and treatment. Neurology 58 (Suppl. 1), 563-570.
91. Olsen, L., Nyström, B., and Seiger, Å . (1973). Monoamine fluorescent histochemistry of human post-mortem brain. Brain Res. 63 , 231-247.
92. Papavasiliou, P.S., Cotzias, G.C., Dölby, S.E., Steck, A.J., Bell, M., and Lawrence, W.H. (1972). Melatonin and Parkinsonism. J. Am. Med. Assoc. 221 , 88-89.
93. Paus, S., Schmitz-Hübsch, T., Wullner, U., Vogel, A., Klockgether, T., and Abele, M. (2007). Bright light therapy in PD: a pilot study. Mov. Disord. 22 , 1495-1498.
94. Petrofsky, J.S., Cuneo, M., Lee, S., Johnson, E., and Lohman, E. (2006). Correlation between gait and balance in people with and without type 2 diabetes in normal and subdued light. Med. Sci. Monit. 12 , CR273-CR281.
95. Pflug. (1976). The effect of sleep deprivation on depressive patients. Acta Psychiatr. Scand. 53 , 148-158.
96. Price, L.H., Spencer, D.D., Marek, K.L., Robbins, R.J., Leranth, C., Farhi, SA., Naftolin, F., Roth, R.H., Bunney, B.S., Hoffer, P.B., et al. (1995). Psychiatric status after human field mesencephalic tissue transplantation in PD. Biol. Psychiatr. 38 , 498-505.
97. Pum, M.E., Huston, J.P., Müller, C.P., and de Souza Silva, M.A. (2008). Visual sensory-motor gating by serotonin activation in the medial prefrontal and occipital, but not in the rhinal, cortices in rats. 153 , 361-372.
98. Pum, M.E., Huston, J.P., Müller, C.P., and de Souza Silva, M.A. (2009). Light-induced activity in the activity box is not aversively motivated and does not show between-trial habituation. Physiol. Behav. 96 , 434-439.
99. Pum, M.E., Rubio, A.R., Carey, R.J., Silva, M.A., and Müller, C.P. (2011). The effects of cocaine on light-induced activity. Brain Res. Bull. 84 , 229-234.
100. Ralph, C.L. (1976). Correlation of melatonin content in pineal gland, blood and brain of some birds and mammals. Am. Zool. 16 , 35-43.
101. Reiff, J. and Jost, W.G. (2011). Drug-induced impulse control disorders in PD. J. Neurol. 258 , S323-S327.
102. Reist, C., Sokolski, K.N., Chen, C.C., Coskinas, E., and Demet, E.M. (1995). The effect of sleep deprivation on motor impairment and retinal adaptation in PD. Prog. Neuro-Psychopharmacol. Biol. Psychiatr. 19 , 445-454.
103. Resnick, H.E., Stansbury, K.B., Harris, T.B., Tirivedi, M., Smith, K., Morgan, P., and Vinik, A.J. (2002). Diabetes, peripheral neuropathy and old age disability. Muscle Nerve 25 , 43-50.
104. Richter, C. (1976). Biological clocks in medicine and psychiatry: The psychology of Curt Richter. (York Press: Baltimore), pp. 97-127.
105. Rittey, C.D., Evans, T.J., Gray, C.E., Paton, R.D., and Bojkowski, C. (1988). Melatonin state in Mendenhall's syndrome. Arch. Dis. Child. 63 , 852-854.
106. Rosenthal, N.E., Sack, D.A., Gillin, J.C., Lewy, AJ., Goodwin, F.K., Davenport, Y., Mueller, P.S., Newsome, D.A., and Wehr, T.A. (1984). Seasonal affective disorder: a description of the syndrome and preliminary findings with light therapy. Arch. Gen. Psychiatr. 41 , 72-80.
107. Roth, W., Wurtman, R.J., and Altschule, M.D. (1962). Morphological changes in the pineal parenchyma cells exposed to continuous light or darkness. Endocrinology 71 , 888-892.
108. Sartucci, F., Orlandi, G., Lucetti, C., Bonucelli, U., Murri, L., Orsini, C., and Porciatti, V. (2003). Changes in pattern electroretinograms to equiluminant red-green and blue-yellow gratings in patients with early PD. J. Clin. Neurophysiol. 20 , 375-381.
109. Schernhammer, E., Chen, H., and Ritz, B. (2006). Circulating melatonin levels: possible link between PD and cancer risk ? Cancer Causes Control 17 , 577-582.
110. Schneider, J.S. (1989). Levodopa-induced dyskinesia in Parkinsonian monkeys: relationship to extent of nigro-striatal damage. Parmacol. Biochem. Behav. 34 , 193-196.
111. Schneider, J.S. (1990). Chronic exposure to low doses of MPTP: II, Neurochemical and pathological consequences in cognitivelyimpaired, motor asymptomatic monkeys. Brain Res. 534 , 25-36.
112. Scholz, E. and Dichgans, J. (1985). Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur. Arch. Psychiatr. Neurol. Sci. 235 , 60-64.
113. Schrag, A. (2004). Psychiatric aspects of PD-an update. J. Neurol. 251 , 795-804.
114. Schrag, A., Dodel, R., Spottke, A., Bornschein, B., Siebert, U., and Quinn, N.P. (2007). Rate of clinical progression in PD. A prospective study. Mov. Disord. 22 , 938-945.
115. Seegal, R.E. and Isaac, W. (1971). Sensory influences upon amphetamine tolerance. Physiol. Behav. 7 , 877-879.
116. Shamir, E., Barak, Y., Shalman, I., Laudon, M., Zisapel, N., Tarrasch, R., Elizur, A., and Weizman, R. (2001). Melatonin treatment for tardive dyskinesia: a double-blind placebo-controlled, crossover study. Arch. Gen. Psychiatr. 58 , 1049-1052.
117. Shaw, K.M. (1977). Hypothalamo-pituitary-adrenal function in Parkinsonian patients and patients treated with melatonin. Curr. Med. Res. Op. 4 , 743-746.
118. Shaw, V.E., Spana, S., Ashkan, K., Benabid, A.L., Stone, J., Baker, G.E., Mitrofanis, J. (2010). Neuroprotection of midbrain DArgic cells in MPTP-treated mice after near-infrared light treatment. J. Comp. Neurol. 518, 25-40.
119. Shaw, K.M., Stern, G.M., and Sandler, M. (1973). Melatonin and parkinsonism. Lancet 1 , 271.
120. Shaw, K.M., Stern, G.M., and Sandler, M. (1975). Melatonin and metatyrosine in the treatment of Parkinsonism. Adv. Neurol. 3 , 115.
121. Shon, Y.M., Lee, K.H., Goerss, S.J., Kim, I.Y., Kimble, C., Van Gompel, J.J., Bennet, K., Blaha, C.D., and Chang, S.Y. (2010). High frequency stimulation of the subthalamic nucleus evokes striatal DA release in large animal model of human DBS neurosurgery. Neurosci. Lett. 475 , 136-140.
122. Stahle, L. and Ungerstedt, U. (1987). On the mode of action of six putative DA receptor agonists on suppression of exploratory behavior in rats. Psychopharmacology 91 , 139-147.
123. Terman, M.T. and Terman, J.S. (2005). Light therapy for seasonal and non seasonal depression: Efficacy, protocol, safety and side effects. CNS Spectrums 10 , 647-663.
124. Thanvi, B.R. and Lo, T.C. (2004). Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad. Med. J. 8 , 452-458.
125. Thompson, S., Lupi, D., Hankins, M.W., Peirson, S.N., and Foster, R.G. (2008). The effects of rod and cone loss on the photic regulation of locomotor activity and heart rate. Eur. J. Neurosci. 28 , 724-729.
126. Togasaki, D.M., Tan, L., Protell, P., Di Monte, D.A., Quik, M., and Langston, J.W. (2001). Levodopa induces dyskinesia in normal squirrel monkeys. Ann. Neurol. 50 , 254-257.
127. Tonnesen, J., Parish, C.L., Sorensen, A.T., Andersson, A., Lundberg, C., Deisseroth, K., Arenas, E., Lindvall, O., and Kokaia, M. (2011). Functional integration of grafted neural stem cell-derived DArgic neurons monitored by optogenetics in an in vitro Parkinsonian model. PloS One 6 , e17560.
128. Touitou, Y., Feure-Montange, M., Proust, J., Klinger, E., and Nakache, J.P. (1985). Age and sex-associated modification of plasma melatonin concentrations in man. Relationship to pathology, malignant or not, and autopsy findings. Acta Endocrinol. (Copenh) 108 , 135-144.
129. Touitou, Y., Smolensky, M.H., and Portaluppi, F. (2006). Ethics standards, and procedures of animals and human chronobiology research. Chronobiol. Int. 23 , 1083-1096.
130. Uccioli, L., Giacomini, P.G., Pasqualetti, P., Digirolamo, S., Ferrigno, P., Montecone, G., Bruno, E., Boccasena, P., Magrini, A., Parisi, L., et al. (1997). Contribution of central neuropathy to postural instability in IDDM patients with peripheral neuropathy. Diabetes Care 20 , 929-934.
131. Uretsky, N.J. and Schoenfeld, R.I. (1971). Effects of L-dopa on the locomotor activity of rats pretreated with 6-hydroxyDA. Nature New Biol. 234 , 157-159.
132. van der Graaf, R. and van Delden, J.J. (2011). Equipoise should be amended, not abandoned. Clin. Trials 8 , 408-416.
133. Vardi, J., Glaubman, H., Rabey, J.M., and Streifler, M. (1978). Myoclonic attacks induced by L-dopa and bromocryptine in Parkinson's patients: a sleep EEG study. J. Neurol. 218 , 35-42.
134. Walker, R.W., Howells, A.R., and Gray, W.K. (2011). The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with PD. Parkinsonism Relat. Disord. 17 , 27-29.
135. Willis, G.L. (2005). The role of ML-23 and other melatonin analogues in the treatment and management of PD. Drug News Perspect. 18 , 437-444.
136. Willis, G.L. (2008a). PD as a neuroendocrine disorder of circadian function: DA-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Rev. Neurosci. 19 , 245-316.
137. Willis, G.L. (2008b). Intraocular microinjections repair experimental PD. Brian Res. 1217 , 119-131.
138. Willis, G.L. and Armstrong, S.M. (1998). Orphan neurons and amine excess: the functional neuropathology of Parkinsonism and neuropsychiatric disease. Brain Res. Rev. 27 , 177-242.
139. Willis, G.L. and Armstrong, S.M. (1999). A therapeutic role for melatonin antagonism in experimental models of PD. Physiol. Behav. 66 , 785-795.
140. Willis, G.L. and Robertson, A.D. (2004). Recovery of experimental PD with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral, 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor. Pharmacol. Biochem. Behav. 79 , 413-429.
141. Willis, G.L. and Robertson, A.D. (2005). Recovery from experimental PD in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23. Pharmacol. Biochem. Behav. 80 , 9-26.
142. Willis, G.L. and Turner, E.J. (2007). Primary and secondary features of PD improve with strategic exposure to bright light: a case series study. Chronobiol. Int. 24 , 521-537.
143. Willis, G.L., Smith, G.C., and McGrath, B.P. (1983). Deficits in locomotor behavior and motor reflex performance after central 6-hydroxydopamine on peripheral L-dopa. Brain Res. 266 , 279-286.
144. Wink, B. and Harris, J. (2000). A model of the Parkinsonian visual system: support for the dark adaptation hypothesis. Vision Res. 40 , 1937-1946.
145. Zharikova, A.D. and Godukhin, O.V. (1985). [Presynaptic auto-regulation of DA release]. Fizol. Zh. SSSR. Im. I. M. Sechenova 71 , 105-112.